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Allogeneic bone marrow transplantation (BMT)' has become a major therapeutic
modality in the treatment of various malignant and nonmalignant hematologic dis-
orders (1-6). However, graft-vs.-host disease (GuHD) causes much morbidity and
mortality after transplantation (7, 8). Since GvHD is mediated by immunocompe-
tent T cells in the graft (9, 10), depletion of T cells from the bone marrow graft
has been successfully applied to reduce the incidence of this complication (11, 12).
On the other hand, T cell depletion from the graft has led to an increased incidence
of graft failure (13-16), which could in part be prevented by increasing the intensity
of the pretransplant conditioning regimen (16-20).
As a result of the genetic disparity between donor and recipient, graft failure may
be due to an immune-mediated rejection by immunocompetent cells in the recip-
vided that these cells are not eliminated by the pretransplant conditioning
and/or by the donor T cells present in the graft. In HLA-nonidentical transplants,
the high incidence of graft rejection (21, 22) can be explained by the general tissue
distribution of these histocompatibiiity antigens, and, in particular, by the expres-
sion of HLA class I and class II antigens on hematopoietic progenitor cells (HPC)
(23-26). However, after the introduction of T cell depletion of the graft to prevent
GuHD, -157o graft rejections have also been observed in HLA-identical transplants
(13-16). In thesecases, antigenic determinants outside the HLA system, called minor
histocompatibility (mH) antigens (27), are likely to be involved in the pathogenesis
of graft rejection. If mH antigens are expressed on HPC, an immune response in
the recipient, directed against these target structures on donor cells, may lead to
elimination of the hematopoietic stem cells from the graft. Therefore, mapping of
mH antigens on HPC is of major importance for understanding the mechanism
of rejection of the hematopoietic graft in bone marrow transplantation.
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Until now, no antibodies against human mH antigens have been available. To
study the expression ofmH determinants on cell populations, specific anti-mH CTL
lines have to be used. (3oulnry et al. (28-30) have been able to generate sever
mH CTL lines from patients who were sensitized in vivo for these antigens by mul-
tiple blood transfusions, or from patients sensitized in viva for these antigens by
allogeneic BMT. Recognition of these mH antigens appeared to be HLA class I
restricted. Apart from the H-Y antigen, expressed on cells of male individuals, five
other mH antigens have been characterized by Goulmy (30) in family and popula-
tion studies.
Previously, we demonstrated the expression of the
topoietic progenitor cells (31), indic
directed against this determinant may lead to rejection of the graft in allogeneic
BMT. Here, we investigated the expression of five mH antigens, designated HA-
oictic progenitor cells, using a cell-mediated cytotoxicity assay(32).
We report the expression of the mH HA-3 determinant on human HPC, whereas
expression of the HA-1, -2, -4, and -5 antigens on these cells is either absent or ex-
tremely low, as measured by antigen-specific growth inhibition of colony forming
cells by cytotoxic T cell lines. Thus, mH antigens appear to be differentially ex-
pressed on human HPC.
totoxic T011Lines against mHAntigens.
￿
The anti-mH CTL lineswere estab-
ibed previously (29, 30). Briefly, 107 PBMC were isolated from patients after
lantation. These cells were used as responder cells, and stimulated by
PBMC that were isolated from the bone marrow transplant recipient before BMT. After
6 d ofculture, the effector cellswere harvested, and further expanded by weekly stimulation
of 10' cells with 106 stimulator mononuclear cells from the recipient before BMT, in the pres-
ence of20% T cell growth factor TCGF; BioWsq Oflinbach, Federal Republic ofGermany).
In this way CTL lines were established, and cryopreserved in liquid nitrogen. Before use,
the CTL lines were thawed for 1 min in a 37'C waterbath, washed, and further expanded
for another 3-5 d in 20% TCGF in RPMI 1640 + 15% prescreened human AB serum.
Phenotype of the CTL Lines.
￿
The phenotypes of the CTL lines were analyzed usingmAbs
against CD2, CD3, CD4, CD8, CD16, and CD19 antigens and FRCS (Becton Dickinson
Immunocytometry Systems, Mountain View, CA).
CytotoxicActivity ofCTLLines,
￿
Cytotoxic activity of the CTL lines was measured in a 4-h
"Cr-release assay as described earlier (33), using PHA-stimulated PBL as target cells. Family
studies and large panels of randomly selected HLA-typed donors were used to define the
specificity ofthe CTL lines and to identify the restricting HLA antigens, as described previ-
ously (30).
Pro"ation ofBoneMarrow (ARK
￿
Normal human bone marrow was obtained, afterinformed
consent, by aspiration from the posterior iliac crests of donors for bone marrow transplanta-
tion. The cells were collected in HBSS with 100 U/ml preservative-free heparin, and were
centrifuged (1,000 g, 30 min, 20'C) over Ficoll-Isopaque (1.077 g/cm3). In some experiments
partially purified bone marrow cells were used, i.e., depleted of monocytes and T lympho-
cytes by incubation with carbonyl-iron particles (45 min, 371C), and subsequentcentrifugation
over Ficoll-Isopaque (34); the interphase cellswere then collected, incubated with 2-amino-
ethylisothiouroniumbromide-pretreated SRBC cells, and centrifuged over Ficoll-Isopaque
to deplete T lymphocytes (35). In most cases bone marrow mononuclear cells, or partially
purified cells were cryopreserved in liquid nitrogen, as described previously (36). Immedi-
ately before use, the cells were thawed for I min in a 37IC waterbath, diluted inhepenbuf1red
RPMI plus 20% FCS (Gibco Laboratories, Grand Island, NY) at OOC, washed once in theVOOGT ET AL.
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same medium, and then washed in RPMI plus 15% AB serum. The cells were resuspended
in RPMI plus 15% AB serum at concentrations of 1-5 x 105 viable cells/ml.
Cell-mediated Cytotoxicity Assay (32).
￿
A quantity of 1.25 x 105 mononuclear bone marrow
cells, or 0.25 x 105 enriched bone marrow cells in 0.25 ml RPMI + 15% AB serum was
mixed with an equal volume of this medium containing CTL. The E/T ratios varied from
1 :2 to 20:1. The cell mixture was centrifuged (1,000 g, 15 s) to establish cell-cell contact be-
tween CTL and the bone marrow cells, and then was incubated for 4-18 h at 37 °C in fully
humidified air with 5% C02. After incubation, the cell mixture was washed once in RPMI
plus 15% AB serum, resuspended in a-modifiedEagle's MEM (a-MEM; Flow Laboratories,
Inc., Irvine, UK), and subsequently cultured for CFU-GM, BFU-E/CFU-E, and CFU-
GEMM. All CTL lines were irradiated (20 Gy) before use to prevent colony formation by
these cells.
CFU-GM.
￿
A quantity of 0.2-1 x 105 bone marrow cells was cultured in 1 ml medium
containing 20% FCS (Rehatuin, Kankakee, IL) 20% leukocyte-conditioned medium (37),
20% a-MEM, and 40% methylcellulose 2.25% in a fully humidified atmosphere of 5 1 70 C02
and 37 °C in 35-mm plastic petri dishes. CFU-GM colonies, defined as granulocytic, mono-
cytic, or eosinophilic aggregates of >20 cells were scored under an inverted microscope on
day 10.
CFU-E/BFU-E.
￿
A quantity of 0.2-1 x 105 bone marrow cells was cultured in 1 ml
medium containing 20% FCS (Rehatuin), 20% leukocyte-conditioned medium, 5% 10-3
M 2-ME, 5% Iscove's modified Dulbeccds medium with 1 U/ml erythropoietin (step III,
Connaught Laboratories Ltd., Willowdale, Canada), 517o deionized serum albumin (Sigma
Chemical Co., St. Louis, MO), 5% human transferrin, and 40% methylcellulose 2 .25% in
35-mm plastic petri dishes in a fully humidified atmosphere of 5% C02 at 37 °C. CFU-E,
defined as clusters of8-64 hemoglobinized cellswere scored on day 7 . The number ofBFU-E
was scored on day 14.
CFU-GEMM.
￿
A quantity of0.2-1 x 105 bone marrow cells was cultured in 1 ml medium
containing 30% ABO-compatible human heparin plasma, 7.5% PHA leukocyte-conditioned
medium (38), 5% 10-3 M 2-ME, 5% deionized serum albumin, 5% human transferrin,
7 .5% Iscove's modified Dulbeccds medium with 1 U/ml erythropoietin, and 40,70 methylcel-
lulose 2.8% in 35-mm plastic petri dishes in a fully humidified atmosphere of 5% C02 at
37°C. CFU-GEMM, defined as colonies containing at least both erythroid and myeloid cells
(39), were scored on day 18.
Normal Values and Calculations of HPC Growth.
￿
Control 100% growth was defined as the
number of colonies cultured from 105 untreated bone marrow mononuclear cells. Normal
values of HPC growth from mononuclear bone marrow cells in our laboratory are 182 t
15 for CFU-GM day 10; 121 t 12 for BFU-E; 149 t 6 for CFU-E; and 16 t 1 for CFU-
GEMM (mean t SE). In cellular cytotoxicity assays, the number of surviving HPC was
expressed as percentage of the total number of colonies in the untreated control cultures.
Results
All cytotoxic T cell lines showed the characteristic phenotype of cytotoxic T cells
(CD2, CD3, CD8+, and CD4, CD16, CD19- ). The CTL lines against the mH an-
tigens HA-1, -2, -4, and -5 all expressed the same restricting HLA-A2 antigen, whereas
HLA-Al was the restriction molecule for the anti-HA-3 CTL line. All anti-mH CTL
lines only showed specificity for the antigen they were directed against when the
target cellsexpressed the restricting HLA antigen identical to the effector cells(Table
I). All bone marrow donors used were typed for the mH antigens using their PHA-
stimulated PBL as target cells in a standard "Cr-release assay.
Previous studies had shown that inhibition ofHPC by incubating the bone marrow
cells for 4 h with antigen-specific CTL lines could be clearly demonstrated using
E/T ratios from 1 :2 to 4:1, leading to nearly complete inhibitionof colony formation2340
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E/T ratio, 20:1, mean t SE of five experiments.
x Using an indirect immunolluorescence technique, as described in Materials and Methods.
by the progenitor cells in the highest E/T ratios (32). When the anti-HA-3 CTL
line was incubated for 4 h with bone marrow cells from HA-3+ donors, a strong
inhibition ofCFU-GM, BFU-E, and CFU-GEMM was observed at all E/T ratios
used (Fig. 1), showing that the mH HA-3 antigen is strongly expressed on human
HPC. Although CFU-E was inhibited to a lesser degree, dose-dependent inhibition
was observed until 80% at the highest E/T ratio (4:1). HPC of HA-3 - HLA-Al'
donors were not inhibited bythe anti-HA-3 CTLlines, demonstrating that the growth
inhibition was mH antigen specific.
In contrast to the mH antigen HA-3, no growth inhibition ofCFU-GM, BFU-E,
CFU-E, andCFU-GEMM from donors expressing the HA-1, HA-2, HA-4, or HA-
5 antigen could beobtained after a 4-h incubation ofthe bone marrow mononuclear
cellswith the anti-HA-1, -2, -4, or -5 CTL lines at these E/T ratios (Figs. 2-5). The
PHA-stimulated target cells from these donors could easily be lysed by these anti-
mH CTL lines.
The possibility was considered that the expression ofthe HA-1, -2, -4, and -5 an-
tigens on HPC was not absent, but much lower than that of the HA-3 antigen. To
further increase the sensitivity ofthe assay, we therefore enriched bone marrow cell
suspensions forHPC by monocyte and T cell depletion (34, 35). These suspensions
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Characteristics of the Anti-mH Cytotoxic T Lymphocyte Lines
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FIGURE 1.
￿
Growth of hematopoietic
progenitor cells (mean t SE) after in-
cubation of bone marrow cells from
HA-3' donors (closedcircles, n = 8) or
HA-3- donors (open circles, n = 8) with
anti-HA-3 CTL, as compared with un-
treated controls.
HLA restriction
Percent lysis of PHA blasts Membrane phenotypet
in 5'Cr-release assay' (percent positive cells)
mH specificity molecule Positive donors Negative donors CD2 CD3 CD4 CD8 CD16 CD19
HA-1 A2 44 t 2 1 t 2 ND ND ND ND ND ND
HA-2 A2 51 ± 7 9 t 2 97 90 16 76 1 1
HA-3 Al 85 ± 3 4 ± 2 98 94 3 95 3 3
HA-4 A2 52 t 4 7 ± 1 99 98 2 98 7 2
HA-5 A2 79 t 8 14 1 3 97 94 4 95 5 4á
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were incubated for 18 h with the anti-mH lines at E/T ratios of20:1 (Table II). Al-
though this procedure increased the sensitivity ofthe assay, it resulted, as demon-
stratedpreviously (32), in nonspecific inhibition ofHPC growth (Table II). Despite
this nonspecific inhibition, there appeared to be some differences in growth inhibi-
tion ofHPC from mH+ and mH- bone marrow donors, using the anti-mH HA-2,
andpossibly HA-5 CTL lines as effector cells. Thus, theremaybe a lowexpression
ofthese antigens on HPC. Due totechnicaldifficulties, theanti-HA-1 CTL line could
not be tested in these experiments. Finally, to determine the killing efficacy ofun-
stimulated cellsby theanti-mH CTL lines, thelysis ofunstimulated peripheral blood
Tlymphocyteswascompared withthatofPHA-stimulatedlymphocytes (Table III).
Although lysis ofunstimulated Tlymphocytes was somewhat less efficient than that
ofPHA blasts, all mH+ donors showed lysis oftheir periferal blood T lymphocytes,
and there was no difference in this respect between HA-2, HA-3, and HA-5. These
results show that whereas the HA-3 antigen was demonstrated to be strongly ex-
pressed on HPC, the HA-1, -2, -4, and -5 antigens seem to be absent or expressed
to a much lower extent.
CFU-GM CFU-E
HA-2
BFU-E
1 2 4
￿
1 2 4
￿
4 1 2 4
￿
1 1 1 1 2 4
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FIGURE 2.
￿
Growth ofhematopoietic progenitor cells
(mean t SE) afterincubation ofbone marrow cells
from HA-1' donors (closed circles, n = 3) or HA-1 -
donors (opencircles, n = 4) with anti-HA-1 CTL, as
compared with untreated controls.
CFU-GEMM
0
FIGURE 3.
￿
Growth of hematopoietic
progenitor cells(mean t SE) afterin-
cubation of bone marrow cells from
HA-2' donors (closed circles, n = 7) or
HA-2- donors (open circles, n = 7)
with anti-HA-2 CTL, as compared
with untreated controls.
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Discussion
In this study, we investigated the expression offivemH antigenson human HPC
using antigen-specific, HLA-restricted CTL lines. A CTL line specific for one of
these antigens, HA-3, showed strong HLA-restricted inhibition of HPC growth in
vitro from HA-3+, but not from HA-3- donors, indicating that this HA-3 antigen
is highly expressed on HPC. Similarto HA-3, we previously demonstrated strong
HLA-restricted inhibition ofmale, but not offemale, HPC by CTL lines against
the mH antigen H-Y (31), showing that the H-Y antigen is also highly expressed
on HPC of (male) donors. In contrast, CTL lines against the mH antigens HA-1,
-2, -4, and -5 showed no or only minor antigen-specific inhibition ofHPC growth
even at high E/T ratios. Although recognition ofthe HA-3 antigen is restricted by
HLA-Al, while recognition of all the other mH antigens is restricted by HLA-A2,
severalargumentsmake it unlikelythatthe observeddifferencesingrowth-inhibition
ofHPC by the anti-mH-CTLs are due to differences in the recognition ofthe res-
tricting HLA antigens.
Firstly, wehave demonstrated previously thatanti-HLA-cytotoxic T lymphocytes
FI 1 2 4
￿
Fz 1 1 4
￿
~
1 2 4
￿
'r a
1 2 4
EFF£CíOR/TARGET RAM
CFU-GM CFU-E
HA-4
CFU-E
￿
BFU.E
HA-5
BFU-E
CFU-GEMM
CFU-GEMM
F1 1 2 4
￿
F 1 1 2 4
￿
F, 1 2 4
￿
Fz
1 1 4
EFFECTOR/TARGET RATIO
FIGURE 4.
￿
Growth of hematopoietic
progenitor cells (mean t SE)afterin-
cubation of bone marrow cells from
HA-4` donors (closedcircles, n = 5) or
HA-4- donors (open circles, n = 5)
with anti-HA-4 CTL, as compared
with untreated controls.
FIGURE 5.
￿
Growth of hematopoietic
progenitorcells(mean t SE)afterin-
cubation of bone marrow cells from
HA-5+ donors (closedcircles, n = 4) or
HA-5- donors (open circles, n = 4)
with anti-HA-5 CTL, as compared
with untreated controls.VOOGT ET AL.
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TABLE II
Colony Growth of Hematopoietic Progenitor Cells after Incubation of Bone Marrow Target Cells with
Elector Cells in a High Effector/Target Cell Ratio and a Prolonged Incubation Time
Percentage growth of HPC"
E/T ratio of 20:1; incubation time, 18 h.
Percentage growth (mean t SE) of untreated controls (n = 6).
can efficiently cause growth inhibitionofHPC (32, Voogt, PJ.,J. H. F. Falkenburg,
W. E. Fibbe, W. F. J. Veenhof, M. Hamilton, B. A. van Krimpen, and R. L. H.
Bolhuis, submitted forpublication). Thishasbeen shownforseveralHLAspecificities,
such as HLA-A2, HLA-B7 (32), and HLA-Cw3, (Voogt, P J., et al., submitted for
publication).
Secondly, wehave shown that recognition ofanother mH antigen, HY, can occur
using different HLA-restricting antigens, such as HLA-A1, HLA-A2, or HLA-B7
(31). These studiesdemonstrated that HPCsofallmale donors tested wereinhibited
in an antigen-specific way by the anti-HYCTLs, provided the donors werepositive
for the restricting HLA specificity (31).
Finally, our results using nonstimulated T lymphocytes ofmH + donors show that
lysis ofthese target cellsoccurred in allcasestested, albeit ifsomewhat less efficiently
when compared with PHA blasts (Table III). However, there was no difference in
this respect between the various anti-mH CTL lines tested.
Thus, the cellularly defined mH antigens appear to be differentially expressed
onhumanHPC. A similarphenomenon has been described forthe major histocom-
patibility class II antigens, HLA-DR but not HLA-DQ, being expressed on HPC
(23, 24).
A cytotoxic alloimmune response ofthe recipient directed against polymorphic
membrane determinants present ondonor cellsmay cause bone marrow graft rejec-
tion, provided that these polymorphic antigens are expressed on the donor HPC.
Therefore, the mH antigens HA-3 and H-Y, which are strongly expressed on HPC,
TABLE III
Lysis of PHA-stimulated or -nonstimulated T Cells by Anti-mH Cytotoxic T Lymphocyte
' Percent lysis in 51Cr-release assay at E/T ratio of 20:1 .
1 Mean t SE of three to four experiments.
CFU-GM BFU-E CFU-GEMM
mH positive mH negative mH positive mH negative mH positive mH negative
Anti-mH-CTL donors donors donors donors donors donors
HA-2 37 1 4 77 1 7 41 1 6 65 1 6 36 1 14 63 1 11
HA-3 2 1 3 110 1 10 0 0 81 1 5 0 0 117 1 7
HA-4 69 1 6 53 1 4 83 1 8 75 1 8 58 1 4 53 1 6
HA-5 37 1 5 42 1 4 50 1 6 70 1 7 40 1 6 68 1 11
mH specificity
PHA
Positive donors
blasts'
Negative donors
T
Positive donors
lymphocytes'
Negative donors
HA-2 46 31 4 1 2 26 1 1 3 1 2
HA-3 75 1 4 2 1 1 42 1 2 3 1 2
HA-5 72 1 5 6 1 2 36 1 3 1 1 12344
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may function as target structures forTlymphocyte-mediated rejectionofthe HPC
from the graft. In contrast, acytotoxic alloreaction ofthe recipientagainst the mH
antigens HA-1, HA-2, HA-4, and HA-5, which are weakly or not present at all on
HPC, may not necessarily cause rejection ofHPC ifthe donor is positive for these
antigens.
Both GvHD and graft rejection are serious complications after allogeneicBMT,
even between HLA genotypically identical siblings. Whereas severe GvHD occurs
in manypatientstransplanted withanunmodified graft, graftrejection isa frequent
complication in patients transplanted with a graft, depleted of T lymphocytes to
prevent GvHD. We previously showed that disparity for the HA-1, -2, -4, or -5 an-
tigens between donor and recipient is correlated with an increased risk ofGvHD
(30). However, HA-3 incompatibility appeared notto be associatedwithGvHD(30).
Conversely, this study suggests thatHA-3,butnot HA-1, -2, -4, or -5 incompatibility
may be a risk factor forgraft rejection. These findings implicate that typing for mH
antigens couldbe ofimportance in the decision whetherornotT lymphocyte deple-
tionofthe graftshould beperformedin anindividualtransplantationbetween HLA-
genotypically identical siblings. Furthermore, in HLA-identical unrelated BMT, if
more than one phenotypically identical donor would be available, typing for mH
antigens may be of help to select the most suitable donor.
In conclusion, ourresults showthat cellularly defined mH antigens are differen-
tially expressed on human HPC. Further mapping ofmH antigens on HPC is of
major interest forgaining insight intothemechanisms ofgraft rejection. Matching
for these antigens between donor and recipient may decrease the risk ofgraft rejec-
tion in allogeneic BMT.
Summary
cted against minor histocompatibility (mH) an-
tigens designated HA-1-5 have been established from peripheral blood of patients
after allogeneic bonemarrow transplantation (BMT), andhave been characterized
using population and family studies. All cell lines showed specific HLA class I-re-
stricted lysis of PHA-stimulated peripheral blood target cells from donors positive
for the particular mH antigens. After 4 h of incubation of the mH antigen HA-
3-specific CTL line with bone marrow cells from HA-3' donors, complete class
I-restricted inhibition ofcolony growth ofthe hematopoietic progenitor cells was
observed even at low E/T ratios, indicating that the HA-3 antigen is strongly ex-
pressed on hematopoietic stem cells. Therefore, this antigen maybe atarget struc-
ture in the immune-mediated rejection ofthe hematopoietic graft in case ofincom-
patibility for this determinant between donor and recipient in allogeneic BMT. In
contrast, incubation ofbone marrow cells with the antigen-specific anti-HA-1, -2,
-4, and -5 CTL lines did not result in growth inhibition of the hematopoietic pro-
genitor cells tested. After a prolonged incubation time and using a very high E/T
ratio, progenitor cells from HA-2+ or HA-5' donors were killed to some extent by
the anti-mH-specific CTLlines, althoughthe growth inhibitionobservedwasminor
andvariable. Ourresults show thatmH antigens are differentially expressed on human
hematopoietic progenitor cells. Therefore, onlysomeoftheseantigens maybetargets
in immune-mediated rejection of the bone marrow graft.
Receivedforpubli May 1988 and an revisedform 15 August 1988.VOOGT ET AL.
￿
2345
References
1 . Thomas, E. D., C. D. Buckner, R. A. Clift, A. Fefer, F L. Johnson, P E. Neiman, G. E.
Sale,J. E. Sanders, J. W Singer, H. Shulman, R. Storb, and P L. Weiden. 1979. Marrow
transplantation for acute non-lymphoblastic leukemia in first remission. N. Engl. J. Med.
30:597.
2 . Thomas, E. D., J. E. Sanders, N. Flournoy, F L. Johnson, C. D. Buckner, R. A. Clift,
A. Fefer, B. W. Goodell, R. Storb, and P L. Weiden. 1979. Marrow transplantation for
patients with acute lymphoblastic leukemia in remisssion. Blood. 54:468.
3 . Goldman, J. M., J. F Apperley, L. Jones, R. Marcus, A. W. G. Goolden, R. Batchelor,
G. Gale, H. Waldmann, C. D. Reid, J. Hows, E. Gordon-Smith, and D. A. G. Galton.
1986. Bone marrow transplantation for patients with chronic myeloid leukemia. N. Engl.
j. Med. 314:202.
4. Storb, R., E. D. Thomas, C. D. Buckner, F R. Appelbaum, J. E. Sanders, P Stewart,
K. M. Sullivan, and R. P Witherspoon. 1984. Marrow transplantation for aplastic
anaemia. Semin. Hematol. 21:27.
5 . Bortin, M. M., and A. Rimm. 1977. Severe combined immunodeficiency: characteriza-
tion of the disease and results of transplantation. JAMA U.. Am. Med. Assoc.). 238:591.
6. O'Reilly, R. J., J. Brochstein, R. Sinsmore, and D. Kirkpatrick. 1984. Marrow trans-
plantation for congenital disorders. Semin. Hematol. 21 :188.
7 . Glucksberg, H ., R. Storb, A. Fefer, C. D. Buckner, P E. Neiman, R. A. Clift, K. G.
Lerner, and E. D. Thomas. 1974. Clinical manifestations of graft-versus-host-disease in
human recipients ofmarrow from HL-A matched sibling donors. Transplantation (Balti-
more). 18:295.
8. Thomas, E. D., R. Storb, R. A. Clift, A. Fefer, F L. Johnson, P E. Neiman, K. G.
Lerner, H . Gluckberg, and C. D. Buckner. 1975 . Bone marrow transplantation. N. Engl.
J Med. 292 :832.
9. Korngold, R., and J. Sprent. 1978. Lethal graft-versus-host disease after bone marrow
transplantation across minor histocompatibility antigens in mice.J Exp. Med. 148:1687.
10. Billingham, R. E. 1966-1967 . The biology ofgraft-versus-host reactions. Harvey Lect. 62:21.
11 . Martin, P J., J. A. Hansen, R. Storb, and E. D. Thomas. 1987. Human marrow trans-
plantation: an immunological perspective. Adv. Immunol. 40:379.
12 . Neudorf, S., A. Filipovich, N. Ramsay, and J. Kersey. 1984. Prevention and treatment
of acute graft-versus-host disease. Semin. Hematol. 21:91.
13 . Martin, P. J., J. A. Hansen, C. D. Buckner, J. E. Sanders, H. J. Deeg, P. Stewart, F. R.
Appelbaum, R. A. Clift, A. Fefer, R. P. Witherspoon, M. S. Kennedy, K. M. Sullivan,
N. Flournoy, R. Storb, and E. D. Thomas. 1985. Effects of in vitro depletion of T cells
in HLA-identical allogeneic marrow grafts. Blood. 66:654.
14. Mitsuyasu, R. T., R. E. Champlin, R. P Gale, W. G. Ho, C. Lenarsky, M. Selch, R.
Elashoff, J . V. Giorgi, D. Winston, J. Wells, P Terasaki, R. Billing, and S. Feig. 1985.
Treatment ofdonor bone marrow with monoclonal antiTcell antibody and complement
for the prevention of graft versus host disease. Ann. Intern. Med. 105:20.
15. Waldmann, H., G. Hale, G. Cividalli, Z. Weshler, D. Manor, E. A. Rachmilewitz, A.
Polliack, R. Or, L. Weirs, S. Samuel, C. Brautbar, and S. Slavin. 1984. Elimination of
graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a mono-
clonal rat anti-human lymphocyte antibody (Campath-1). Lancet. ii :483.
16. Patterson, J., H. G. Prentice, M. Brenner, et al. 1986. Graft rejection following HLA-
matched T-lymphocyte depleted bone marrow transplantation. Br. J Haematol. 63:221.
17. Irondo, A., V. Hermosa, C. Richard, E. Conde, C. C. Bello, J. Garyo, J. Baro, and Z.
Zubizarreta. 1986. Graft rejection following T lymphocyte depleted bone marrow trans-
plantation with two different TBI regiments. Br. J Haematol. 63 :246.
18. O'Reilly, R. J., B. Shank, N. Collins, N. Kernan, J. Brochstein, C. Keever, R. Dins-
more, D. Kirkpatrich, H. Castro-Malaspina, I. Cunningham, N. Flomenberg, and R.2346
￿
MINOR HISTOCOMPATIBILITY ANTIGENS ON HUMAN STEM CELLS
Burns. 1985. Increased total body irradiation (TBI)abrogates resistanceto HLA-matched
marrow graftsdepleted ofT cells by lectin agglutination and E-rosette depletion (SBA-E-
BMT). Exp. Hematol. 13:406 (abstr.).
19. Or, R., Z. Weshler, G. Lugassy, D. Sterner-Salz, E. Galun, L. Weiss, S. Samuel, A. Pol-
liack, E. A. Rachmilewitz, H . Waldmann, and S. Slavin. 1985 . Total lymfoid irradiation
(TLI) as adjunct immunosuppressor for preventing late graft failure (LGF) associated
with T-cell depleted marrow allograft. Exp. Hematol (NY). 13:409 (Abstr.).
20. Fisher, A., S. Blancke, F. Veber, M. Delaage, C. Mawas, C. Griscelli, F Le Deist, M.
Lopez, D. Olive, and G. Janossy. 1986. Prevention of graft-failure by an anti LFA-1 mono-
clonal antibody in HLA-mismatched bone-marrow transplantation. Lancet. ii:1058.
21 . Filipovich, A. H., N. K. C. Ramsay, and P. McGlave. 1983. Mismatched bone marrow
transplantation at the University of Minnesota. Use of related donors other than HLA-
MLC identical siblings and T cell depletion. In Recent Advances in Bone Marrow Trans-
plantation. R. P Gale, editor. Alan R. Liss, Inc., New York. 769-783.
22 . O'Reilly, R. J ., N. H. Collins, N. Kernan, J . Brochstein, R. Dinsmore, D. Kirkpatrick,
S. Sienna, C. Keever, B. Jordan, B. Shank, L. Wolf, B. Dupont, and Y. Reisner. 1985 .
Transplantation of marrow depleted T cells by soy bean agglutination and E rosette deple
tion: major histocompatibility related graftresistance in leukemic transplant recipients.
Transplant. Proc. 17 :455 .
23 . Falkenburg, J. H . F., J. Jansen, N. Van der Vaart-Duinkerken, W. FJ. Veenhof, J. Blot-
kamp, H . M. Goselink, J . Parlevliet, and J. J. Van Rood. 1984. Polymorphic and mono-
morphic HLA-DR determinants on human hematopoietic progenitor cells. Blood. 63:1125.
24 . Falkenburg,J. H. F, W. E. Fibbe, H. M. Goselink,J. J. Van Rood, andJ. Jansen. 1985.
Human hematopoietic progenitor cells in long-term cultures express HLA-DR antigens
and lack HLA-DQ antigens. J. Exp. Med. 162 :1359.
25 . Fitchen, J. H ., K. A. Foon, and M. J. Cline. 1981. The antigenic characteristics ofhema-
topoietic stem cells. N. Engl. J Med. 305:17.
26. Sieff, C., D. Bicknell, G. Caine, J. Robinson, G. Lam, and M. F. Greaves. 1982. Changes
in cell surface antigen expression during hemopoietic differentiation. Blood. 60:703.
27 . Loveland, B., and E. Simpson. 1986. The non-MHC transplantation antigens: neither
weak nor minor. Immunol. Today. 7:223.
28. Goulmy, E., A. Termijtelen, B. A. Bradley, and J. J. Van Rood. 1977 . Yantigen killing
by T cells of women is restricted by HLA. Nature (Loud.). 266:544.
29. Goulmy, E., J. W. Gratama, E. Blokland, F. E. Zwaan, and J. J. Van Rood. 1983. A
minor transplantation antigen detected by MHC restricted cytotoxic T lymphocytes during
graft-versus-host disease. Nature (Lond). 302:159.
30. Goulmy, E. 1988. Minor histocompatibility antigens in man and their role in transplan-
tation. Transplant. Rev. 2:29.
31 . Voogt, P. J., E. Goulmy, W. E. Fibbe, W. F J. Veenhof, A. Brand, and J. H. F. Falken-
burg. 1988. Minor histocompatibility antigen H-Y is expressed on human hematopoietic
progenitor cells. J Clin. Invest. 82:906.
32. Voogt, P. J., W. E. Fibbe, W. F. J. Veenhof, A. Brand, E. Goulmy, J. J. Van Rood, and
J . H . F Falkenburg. 1987. Cell mediated lysisof human hematopoietic progenitor cells.
Leukemia (Baltimore). 1:427 .
33. Goulmy, E. 1982. HLA-A, B restriction of cytotoxic T cells. In HLA-typing; Method-
ology and Clinical Aspects. S. Ferrone and B. G. Solheim, editors. CRC Press, Boca
Raton. 105-122.
34. Lundgren, G., Ch. F. Zukoshi, and G. Moller. 1968. Differential effects ofhuman granu-
locytes and lymphocytes on human fibroblasts in vitro. Clin. Exp. Immunol. 3 :817.
35. Madsen, M ., and H. E. Johnson. 1979. A methodological study of E-rosette formation
using AETtreated sheep red blood cells. J Immunol. Methods. 27:61 .
36. Falkenburg, J. H. F., W. E. Fibbe, N. Van der Vaart-Duinkerken, M. E. Nichols, PVOOGT ET AL.
￿
2347
Rubinstein, andJ . Jansen. 1985. Human erythroid progenitors express Rhesus antigens.
Blood. 66:660.
37 . Iscove, N. N., J. S. Senn, J . E. Till, and E. A. McCulloch. 1971. Colony formation by
normal and leukemic human marrow cells in culture: effect ofconditioned medium from
human leucocytes. Blood. 37 :1 .
38 . Ash, R. C., R. A. Detrick, and E . D. Zanjani. 1981. Studies of human pluripotential
hemopoietic stem cells (CFU-GEMM) in vitro. Blood. 58:309.
39 . Messner, H. A. 1984. Human stem cells in culture. Clin. Hematol. 13:393.